Skip to main content
Premium Trial:

Request an Annual Quote

Mainz Biomed Partners With German Diagnostic Laboratory to Offer ColoAlert Test

NEW YORK – Mainz Biomed said on Tuesday that it has entered into a strategic partnership with German diagnostic laboratory Ärztliches Labor Dr. Buhlmann to further strengthen its presence in the German market. 

The collaboration will offer Mainz Biomed greater access to Germany's private health insurance segment for its ColoAlert colorectal cancer screening test, the company said in a statement. Ärztliches Labor Dr. Buhlmann offers molecular diagnostics, genetics, HLA testing, and infectious disease testing to clients under both state and private insurance. 

"Partnering with Dr. Buhlmann's laboratory not only has the potential to further expedite the adoption of ColoAlert in Germany but also aligns with our core mission of facilitating early CRC detection globally," Mainz Biomed Chief Commercial Officer Darin Leigh said in a statement. "We look forward to leveraging her network across both public and private sectors and benefiting from her considerable expertise in pioneering molecular diagnostic tests."

ColoAlert is a PCR-based multiplex test measuring tumor markers in DNA from stool samples and is available in multiple European countries. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.